ArticleJournal of the Endocrine Society2026
Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an efficacy of 50%. Some biomarkers can predict patient response, potentially benefiting nonresponders by using personalized treatment approaches. The ACROFAST study revealed that the probability of disease control was 2.53 times higher (CI 1.30-4.80) with personalized treatment, and insulin-like growth factor 1 (IGF1) normalization occurred in 78% vs 53% of patients, compared with standard treatment ( Objective: To evaluate the cost-effectiveness of personalized medicine based on predictive biomarkers, from the results of the ACROFAST study. Methods: Post hoc analysis from the ACROFAST study comparing cost-effectiveness of a protocol of medical treatment based on predictive biomarkers to fgSRLs (n = 32) vs standard treatment (n = 36) for 12 months. Costs analyzed were visits, examinations, study of biomarkers (121€/patient), and pharmacological treatment according to the prices established by the Spanish National Health Care System. Medium-term costs were evaluated, considering a projection of up to 2 years in uncontrolled cases, assuming positive and negative scenarios with additional monitoring costs and a 25% likelihood of disease progression per follow-up visit. Results: The personalized protocol reduced the average cost per patient required to achieve disease control by 22% (15 127€ vs 19 420€). These results represent an annual saving of 15 263€ per patient achieving hormonal control compared to the standard treatment. Conclusion: Personalized medicine, using a relatively straightforward biomarker-based protocol, enables a greater proportion of patients to attain hormonal control and proves to be a cost-effective strategy for managing acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.